Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
SUBLOCADE Rapid Initiation Study
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03993392
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03977012
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03861338
- Locations
- 🇺🇸
Substance Treatment Research Service (STARS) of Columbia University, New York, New York, United States
Virginia Opioid Overdose Treatment InitiatVE
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 19
- Registration Number
- NCT03818399
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Stony Brook University
- Registration Number
- NCT03740243
Add-on Buprenorphine At Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 180
- Registration Number
- NCT03646058
- Locations
- 🇫🇷
Ch Perrens, Bordeaux, France
🇫🇷CHU Bicêtre, Le Kremlin-Bicêtre, France
🇫🇷Hospices Civils de Lyon, Lyon, France
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 10
- Registration Number
- NCT03608696
- Locations
- 🇺🇸
Thomas Jefferson University Hosptial, Philadelphia, Pennsylvania, United States
Optimal Treatment of Veterans With PTSD and Comorbid OUD
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 38
- Registration Number
- NCT03605342
- Locations
- 🇺🇸
VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States
🇺🇸Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States
HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 159
- Registration Number
- NCT03583138
- Locations
- 🇺🇸
Howard University, Washington, District of Columbia, United States
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.